Hopp til hovedinnhold

M05B  - Midler med effekt på benstruktur og mineralisering

Sist oppdatert: Sist revidert:
Sist revidert av:
  • Legemiddelkapittelet bygger på informasjon fra Felleskatalogen, Norsk Legemiddelhåndbok og diverse farmakologiske oppslagsverk
  1. Ross JR, Saunders Y, Edmonds PM, Patel S, Broadley KE, Johnston SRD. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 2003; 327: 469. British Medical Journal  
  2. Kamby C, Pedersen L, Kristensen B. Bisfosfonater ved solide maligne sygdomme. Ugeskr Læger 2005; 167: 379-82. PubMed  
  3. Ross JR, Saunders Y, Edmonds PM et al. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 2003; 327: 469-72. British Medical Journal  
  4. Pavlakis N, Stockler M. Bisphosphonates for breast cancer. (Cochrane Review). I: The Cochrane Library, Issue 1, 2002. The Cochrane Library  
  5. Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-68. PubMed  
  6. Diel IJ, Solmayer EF, Costa SD et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998; 339: 357-63. New England Journal of Medicine  
  7. Saarto T, Blomqvist C, Virkkunen P et al. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol 2001; 19: 10-7. PubMed  
  8. Powles T, Paterson S, Kanis JA et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 2002; 20: 3219-24. PubMed  
  9. Løkken P, Skoglund LA, Skjelbred P. Kjeveosteonekrose ved bisfosfonatbehandling. Tidsskr Nor Lægeforen 2007; 127: 1945-7. PubMed  
  10. Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22: 1479-91. pmid:17663640 PubMed  
  11. Khan AA, Sándor GK, Dore E, et al. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. J Rheumatol 2008; 35: 1391-7. pmid:18528958 PubMed  
  12. Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2013. pmid:23712442 PubMed  
  13. Sharma A, Chatterjee S, Arbab-Zadeh A, et al. Risk of serious atrial fibrillation and stroke with use of bisphosphonates: Evidence from a meta-analysis. Chest 2013; 144: 1311-22. doi:10.1378/chest.13-0675 DOI  
  14. Vinogradova Y, Coupland C, Hippisley-Cox J. Exposure to bisphosphonates and risk of gastrointestinal cancers: series of nested case-control studies with QResearch and CPRD data. BMJ 2013; 346: f114. BMJ (DOI)  
  • Olav Spigset, overlege, professor dr. med., Avdeling for klinisk farmakologi, St. Olavs Hospital